April 21, 2022
Headwinds, rough waters, etc.
First, it’s refreshing when a company doesn’t use the normal corporate code words when talking about their franchises. Now right off the bat let’s make it clear things are not going badly for Abbott and the Libre. There are however signs to be aware of particularly when it comes to domestic sales and the state of the Libre3. Here is our take on what was and was not said yesterday during the Abbott earnings call-
1. It’s going to be a long time before the FDA approves the Libre3 and the FDA isn’t . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
